Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143325 · ClinicalTrials.gov registry record · Phase 3
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
A Phase 3 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT00143325: Completed Phase 3 study of Smoking Cessation, sponsored by Pfizer.
NCT00143325 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 730 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00143325, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.
Conditions Studied
Interventions
- DRUG varenicline (CP-526,555)
Study Locations (20)
Other
- Pfizer Investigational Site - Brussels
- Pfizer Investigational Site - Edegem
- Pfizer Investigational Site - Ghent
- Pfizer Investigational Site - Caen
- Pfizer Investigational Site - Clermont-Ferrand
- Pfizer Investigational Site - Limeil-Brévannes
- Pfizer Investigational Site - Metz
- Pfizer Investigational Site - Paris
- Pfizer Investigational Site - Vandœuvre-lès-Nancy
- Pfizer Investigational Site - Amsterdam
- Pfizer Investigational Site - Enschede
- Pfizer Investigational Site - Maastricht
- Pfizer Investigational Site - Zutphen
California
- Pfizer Investigational Site - Palo Alto
- Pfizer Investigational Site - Santa Ana
Connecticut
- Pfizer Investigational Site - Farmington
Kentucky
- Pfizer Investigational Site - Lexington
Massachusetts
- Pfizer Investigational Site - Worcester
Oregon
- Pfizer Investigational Site - Portland
Surrey
- Pfizer Investigational Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
What the finished NCT00143325 record still lists
NCT00143325 is an interventional study that assigns participants to a tested intervention. The registered 730 participants enrollment target is mid-sized for trials with a published cap, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which varenicline (CP-526,555) is the first listed.
NCT00143325 names 20 study sites across 7 states, led by Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00143325 about?
NCT00143325 is a clinical study titled "An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation". Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.
What is the current status of trial NCT00143325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2005-01. Estimated completion is 2006-06.
What conditions does trial NCT00143325 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00143325?
The interventions under investigation include: varenicline (CP-526,555) (DRUG).
Who is sponsoring clinical trial NCT00143325?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00143325 being conducted?
This trial has 20 study locations across California, Connecticut, Kentucky, Massachusetts, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00143325's enrollment target sits among peer trials
730 36th of 188 higher than 153 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT07312162 · 730 participants
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia